Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 669-677

  Meurice, Nathalie ^a   Wang, Lei ^b   Lipinski, Christopher A ^d   Yang, Zhongbo ^d   Hulme, Christopher ^c   Loftus, Joseph C ^d  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b Tripos International   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE BAND 4.1 PROTEIN; EZRIN; FOCAL ADHESION KINASE 2; MOESIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 12A10; PROTEIN KINASE INHIBITOR; RADIXIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOMA; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR INTERACTION; MOLECULAR MODEL; PHARMACOPHORE; PROTEIN DOMAIN; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; X RAY DIFFRACTION;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETAL PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; FOCAL ADHESION KINASE 2; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLIOMA; HUMANS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS;

EID: 77249142358     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901247a     Document Type: Article

References (42)

1. Sperandio, O.; Miteva, M.; Segers, K.; Nicolaes, G. A. F.; Villoutreix, B. O. Screening outside the catalytic site: inhibition of macromolecular interactions through structure-based virtual ligand screening experiments. Open Biochem. J. 2008, 2, 29-37.
2. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450, 1001-1009.
3. Domling, A. Small molecular weight protein-protein interaction antagonists;an insurmountable challenge? Curr. Opin. Chem. Biol. 2008, 12, 281-291.
4. Ruffner, H.; Bauer, A.; Bouwmeester, T. Human protein-protein interaction networks and the value for drug discovery. Drug Discovery Today 2007, 12, 709-716.
5. Lewis, J. A.; Lebois, E. P.; Lindsley, C. W. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr. Opin. Chem. Biol. 2008, 12, 269-280.
6. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2, 358-364.
7. Zhao, Z.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huber, H. E.; Duggan, M. E.; Lindsley, C. W. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.2 Bioorg. Med. Chem. Lett. 2008, 18, 49-53.
8. Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Gupta, V.; Lattanze, J.; Ramachandren, K.; Carver, T. E.; Petrella, E. C.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Lu, T. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 2005, 15, 765-770.
9. Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Marugan, J.; Raboisson, P.; Schubert, C.; Koblish, H. K.; Zhao, S.; Franks, C. F.; Lattanze, J.; Carver, T. E.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Maroney, A. C.; Lu, T. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg. Med. Chem. Lett. 2006, 16, 3310-3314.
10. Avraham, S.; London, R.; Fu, Y.; Ota, S.; Hiregowdara, D.; Li, J.; Jiang, S.; Pasztor, L. M.; White, R. A.; Groopman, J. E..; et al. Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J. Biol. Chem. 1995, 270, 27742-27751.
11. 2+-induced regulation of ion channel and MAP kinase functions. Nature 1995, 376, 737-745.
12. Sasaki, H.; Nagura, K.; Ishino, M.; Tobioka, H.; Kotani, K.; Sasaki, T. Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J. Biol. Chem. 1995, 270, 21206-21219.
13. Mangeat, P.; Roy, C.; Martin, M. ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol. 1999, 9, 187-192.
14. de Pereda, J. M.; Wegener, K. L.; Santelli, E.; Bate, N.; Ginsberg, M. H.; Critchley, D. R.; Campbell, I. D.; Liddington, R. C. Structural basis for phosphatidylinositol phosphate kinase type I-γ binding to talin at focal adhesions. J. Biol. Chem. 2005, 280, 8381-8386.
15. Garcia-Alvarez, B.; de Pereda, J. M.; Calderwood, D. A.; Ulmer, T. S.; Critchley, D.; Campbell, I. D.; Ginsberg,M. H.; Liddington, R. C. Structural determinants of integrin recognition by talin. Mol. Cell 2003, 11, 49-58.
16. Hamada, K.; Shimizu, T.; Matsui, T.; Tsukita, S.; Hakoshima, T. Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J. 2000, 19, 4449-4462.
17. Wegener, K. L.; Partridge, A. W.; Han, J.; Pickford, A. R.; Liddington, R. C.; Ginsberg, M. H.; Campbell, I. D. Structural basis of integrin activation by talin. Cell 2007, 128, 171-182.
18. Edwards, S. D.; Keep, N. H. The 2.7 Å crystal structure of the activated FERM domain of moesin: an analysis of structural changes on activation. Biochemistry 2001, 40, 7061-7068.
19. Li, Q.; Nance, M. R.; Kulikauskas, R.; Nyberg, K.; Fehon, R.; Karplus, P. A.; Bretscher, A.; Tesmer, J. J. Self-masking in an intact ERM-merlin protein: an active role for the central alphahelical domain. J. Mol. Biol. 2007, 365, 1446-1459.
20. Pearson, M. A.; Reczek, D.; Bretscher, A.; Karplus, P. A. Structure of theERMprotein moesin reveals theFERMdomain fold masked by an extended actin binding tail domain. Cell 2000, 101, 259-270.
21. Smith, W. J.; Nassar, N.; Bretscher, A.; Cerione, R. A.; Karplus, P. A. Structure of the active N-terminal domain of ezrin. Conformational and mobility changes identify keystone interactions. J. Biol. Chem. 2003, 278, 4949-4956.
22. Lietha, D.; Cai, X.; Ceccarelli, D. F.; Li, Y.; Schaller, M. D.; Eck, M. J. Structural basis for the autoinhibition of focal adhesion kinase. Cell 2007, 129, 1177-1187.
23. Dunty, J. M.; Gabarra-Niecko, V.; King, M. L.; Ceccarelli, D. F.; Eck, M. J.; Schaller, M. D. FERM domain interaction promotes FAK signaling. Mol. Cell. Biol. 2004, 24, 5353-5368.
24. Dunty, J. M.; Schaller, M. D. The N termini of focal adhesion kinase family members regulate substrate phosphorylation, localization, and cell morphology. J. Biol. Chem. 2002, 277, 45644-45654.
25. 2+/calmodulin to FERM F2 α2 helix and thus forming its dimer. Biochem. J. 2008, 410, 513-523.
26. Lipinski, C. A.; Tran, N. L.; Dooley, A.; Pang, Y. P.; Rohl, C.; Kloss, J.; Yang, Z.; McDonough, W.; Craig, D.; Berens, M. E.; Loftus, J. C. Critical role of the FERM domain in Pyk2 stimulated glioma cell migration. Biochem. Biophys. Res. Commun. 2006, 349, 939-947.
27. Loftus, J. C.; Yang, Z.; Tran, N. L.; Kloss, J.; Viso, C.; Berens, M. E.; Lipinski, C. A. The Pyk2 FERM domain as a target to inhibit glioma migration. Mol. Cancer Ther. 2009, 8, 1505-1514.
28. Moreira, I. S.; Fernandes, P. A.; Ramos, M. J. Hot spots. A review of the protein-protein interface determinant amino-acid residues. Proteins 2007, 68, 803-812.
29. Lipinski, C. A.; Tran, N. L.; Menashi, E.; Rohl, C.; Kloss, J.; Bay, R. C.; Berens, M. E.; Loftus, J. C. The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 2005, 7, 435-445.
30. Lipinski, C. A.; Tran, N. L.; Viso, C.; Kloss, J.; Yang, Z.; Berens, M.; Loftus, J. C. Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts. J. Neuro-Oncol. 2008, 90, 181-189.
31. Zhao, Y.; Lou, D.; Burkett, J.; Kohler, H. Chemical engineering of cell penetrating antibodies. J. Immunol. Methods 2001, 254, 137-145.
32. Hirao, M.; Sato, N.; Kondo, T.; Yonemura, S.; Monden, M.; Sasaki, T.; Takai, Y.; Tsukita, S. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rhodependent signaling pathway. J. Cell Biol. 1996, 135, 37-51.
33. Hamada, K.; Shimizu, T.; Yonemura, S.; Tsukita, S.; Hakoshima, T. Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. EMBO J. 2003, 22, 502-514.
34. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 1998, 280, 1-9.
35. Eck, M. J.; Dhe-Paganon, S.; Trub, T.; Nolte, R. T.; Shoelson, S. E. Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell 1996, 85, 695-705.
36. Li, S.-C.; Zwahlen, C.; Vincent, S. J. F.; McGlade, C. J.; Kay, L. E.; Pawson, T.; Forman-Kay, J. D. Structure of a Numb PTB domain-peptide complex suggests a basis for diverse binding specificity. Nat. Struct. Mol. Biol. 1998, 5, 1075-1083.
37. Zhang, Z.; Lee, C.-H.; Mandiyan, V.; Borg, J.-P.; Margolis, B.; Schlessinger, J.; Kuriyan, J. Sequence-specific recognition of the internalization motif of the Alzheimer's amyloid precursor protein by the X11 PTB domain. EMBO J. 1997, 16, 6141-6150.
38. Keil, M.; Exner, T. E.; Brickmann, J. Pattern recognition strategies for molecular surfaces: III. Binding site prediction with a neural network. J. Comput. Chem. 2004, 25, 779-89.
39. Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 2003, 46, 499-511.
40. Jain, A. N. Virtual screening in lead discovery and optimization. Curr. Opin. Drug Discovery Dev. 2004, 7, 396-403.
41. Pham, T. A.; Jain, A. N. Parameter estimation for scoring protein-ligand interactions using negative training data. J. Med. Chem. 2006, 49, 5856-68.
42. Lipinski, C. A.; Tran, N. L.; Bay, C.; Kloss, J.; McDonough, W. S.; Beaudry, C.; Berens, M. E.; Loftus, J. C. Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol. Cancer Res. 2003, 1, 323-332.